Establishment Labs® Appoints Taylor Harris to Board of Directors

About this update from Establishment Labs Holdings Inc.

NEW YORK, June 29, 2026 --( BUSINESS WIRE )-- Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Taylor Harris to its Board of Directors. Mr. Harris brings more than 25 years of experience in corporate finance, executive leadership and board governance across healthcare, medical technology and life sciences companies. He currently serves on the board of directors of Procept BioRobotics and previously served as a director of Omada Health and Endologix. Most recently, he served as Chief Executive Officer of Cutera, Inc. Prior to Cutera, Mr. Harris served as Chief Financial Officer of MyoKardia, where he helped guide the company through its acquisition by Bristol Myers Squibb in a transaction valued at $13.1 billion. Earlier in his career, he served as Chief Financial Officer of Zeltiq Aesthetics through its acquisition by Allergan and as Chief Financial Officer of Thoratec Corporation through its acquisition by St. Jude Medical. He also spent more than a decade at JPMorgan Chase & Co. in healthcare equity research and investment banking roles. "Taylor is a highly regarded and accomplished healthcare executive whose experience will help Establishment Labs through its next phase of growth," said Nick Lewin, Chairman of the Board of Establishment Labs. "Importantly, he brings deep expertise in the medical aesthetics industry and has helped lead and create substantial value at multiple healthcare companies. His perspective on sustained growth through innovation and focus on shareholder value creation will be a tremendous asset to Establishment Labs as it becomes a true leader in the global aesthetics market." "I am honored to join the Board of Establishment Labs at such an exciting time," said Mr. Harris. "The company has built a reputation for innovation, quality and a strong commitment to improving outcomes for women around the world, and is in a position to become one of the most important companies in aesthetics and healthcare. I look forward to being part of the journey." About Establishment Labs Establishment Labs Holdings Inc. is a global medical device company dedicated to improving women's health and wellness in breast aesthetics and reconstruction through the power of science, engineering, and technology. The company offers a portfolio of solutions for breast health, breast aesthetics, and breast reconstruction in over 100 countries. With five million Motiva® devices delivered to plastic and reconstructive surgeons since 2010, the company's products have created a new standard for safety and patient satisfaction. The company's minimally invasive platform consists of Mia Femtech®, a unique minimally invasive experience for breast harmonization, and Preservé™, a breast tissue preserving and minimally invasive technology for primary breast augmentation and primary mastopexy augmentation. GEM® is a next generation minimally invasive system for gluteal ergonomic modeling currently undergoing an IRB approved pivotal study. The Motiva Flora® tissue expander is used to improve outcomes in breast reconstruction following breast cancer and is the only regulatory-approved expander in the world with an integrated port using radio-frequency technology that is MRI conditional. Zensor™ is an RFID technology platform used to safely identify implantable devices from outside the body, and includes the company's first biosensor Zenº™, currently part of an IRB approved pivotal study to measure core breast temperature. These solutions are supported by over 200 patent applications in 20 separate patent families worldwide and over 100 scientific and clinical studies and publications in peer reviewed journals. Establishment Labs manufactures at two facilities in Costa Rica compliant with all applicable regulatory standards under ISO13485:2024 and FDA 21 CFR 820. Please visit our website for additional information at www.establishmentlabs.com .

View stock analysis, news, and events for Establishment Labs Holdings Inc.